EP Patent

EP2444085B1 — Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer

Assigned to University of California · Expires 2015-03-18 · 11y expired

What this patent protects

The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.

USPTO Abstract

The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP2444085B1
Jurisdiction
EP
Classification
—
Expires
2015-03-18
Drug substance claim
No
Drug product claim
No
Assignee
University of California
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.